Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular Denervation

Theorist position for analysis 687fb884-6d31-47c3-a83f-074bad980db6: Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular Denervation

Source basis: The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis (Nature Communications, 2025, DOI 10.1038/s41467-025-62351-3). The stored gap context says: NMJ denervation study identified myeloid cell involvement; cell-autonomous vs. non-cell-autonomous contributions of FUS mutations to NMJ pathology were not separated in the experimental design.

Primary hypothesis: mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inflammatory signaling is not merely an associated signature; it is a testable mechanism that can explain the open question: What are the relative contributions of cell-autonomous motor neuron mechanisms versus non-cell-autonomous astrocyte and microglia mechanisms in mutant FUS-driven neuromuscular denervation in ALS — and do patient-derived chimeric co-culture systems with isogenic controls reveal independent glial contributions to NMJ dysfunction?

Three candidate claims should be carried forward. First, the strongest causal signal should appear in the cell type or tissue compartment named by the question, not only in bulk disease contrasts. Second, perturbing the axis should shift a proximal molecular phenotype before it shifts a late pathology phenotype, which would help separate cause from consequence. Third, the relevant readout should be stratified by FUS, FUS-, ALS, NMJ, because collapsing across those terms would erase the mechanism the analysis is trying to test.

The priority experiment is isogenic motor-neuron, astrocyte, and microglia chimeric co-cultures with NMJ formation and denervation readouts. A positive result would require concordance across human observational data, disease-relevant cellular models, and at least one perturbation that moves the predicted proximal readout in the expected direction.

Skeptic critique for analysis 687fb884-6d31-47c3-a83f-074bad980db6: Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular Denervation

The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: co-culture systems can exaggerate glial effects and underrepresent muscle and peripheral immune contributions.

The debate should reject any claim that only restates the title. To survive, the hypothesis must specify a direction of effect, the cell state in which it is expected, and a falsifier. For this analysis, a decisive falsifier would be failure to observe the predicted proximal change after perturbing mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inflammatory signaling in the disease-relevant model, even when technical power and cell-state annotation are adequate.

The strongest alternative explanation is that FUS, FUS-, ALS, NMJ mark disease severity rather than mechanism. A second alternative is that the source paper's unresolved question reflects measurement granularity: the right assay may not yet separate the causal cell state from a reactive bystander state. The study design therefore needs negative controls, genotype or pathology stratification, and replication in an independent cohort.

Domain expert assessment for analysis 687fb884-6d31-47c3-a83f-074bad980db6: Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular Denervation

The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inflammatory signaling in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a translational biomarker or intervention point.

For model systems, prioritize human iPSC-derived disease-relevant cells, co-culture or organoid systems only when the question explicitly requires cross-cell interaction, and mouse models only for organism-level timing or NMJ/vascular phenotypes. Biomarkers should be proximal to mechanism: transcriptional module activity, protein localization, lipid or RNA-modification state, spatial vascular coupling, or motor-unit integrity depending on the gap.

The development risk is moderate. The question is specific enough to generate falsifiable work, and it is anchored to The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis. The risk is that therapeutic tractability may lag mechanistic clarity: even if mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inflammatory signaling is causal, the safest intervention point may be an upstream regulator, a cell-state transition, or a biomarker-guided patient subset rather than the named entity itself.